Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Diabetology & Metabolic Syndrome
Published in: Diabetology & Metabolic Syndrome 1/2022

Open Access 01-12-2022 | Diabetes | Research

Diagnostic significance of serum FGD5-AS1 and its predictive value for the development of cardiovascular diseases in patients with type 2 diabetes

Authors: Yongdi Wang, Jian Wang

Published in: Diabetology & Metabolic Syndrome | Issue 1/2022

Login to get access

Abstract

Background

As a result of the continuous rise in the incidence of type 2 diabetes mellitus (T2DM), related cardiovascular diseases (CVDs) have been a main healthy burden worldwide. This study aimed to investigate the potential role of FGD5-AS1 as a biomarker for the diagnosis of T2DM and predicting cardiovascular complications in T2DM.

Methods

Three hundred subjects were recruited in this study, including 100 T2DM patients without CVDs, 100 T2DM patients with CVDs as well as 100 healthy subjects. Plasma FGD5-AS1 level was quantified using RT-qPCR assay. The correlation of FGD5-AS1 level with other key variables was assessed using Pearson correlation analysis. ROC curve analysis was performed to evaluate the diagnostic value of FGD5-AS1 for T2DM and related CVDs. The effect of FGD5-AS1 on AC16 and HA-VSMCs was determined.

Results

FGD5-AS1 level showed a stepwise decrease in individuals with T2DM and CVDs compared to healthy persons. FGD5-AS1 was associated with BMI, systolic blood pressure, diastolic blood pressure, fasting glucose, 2-h postprandial blood glucose, HbA1c, triglycerides, usCRP, and HDL-cholesterol. The ROC analysis indicated FGD5-AS1 had a significant overall predictive ability to diagnose T2DM, T2DM with CVDs, and the combination of both. FGD5-AS1 increases the growth but alleviates apoptosis and fibrosis of high glucose-induced AC16 cells. FGD5-AS1 attenuate the growth and calcification but induced apoptosis of high glucose-treated HA-VSMC cells.

Conclusions

These results suggest that FGD5-AS1 are associated with T2DM and measuring FGD5-AS1 could potentially contribute to T2DM screening and prediction for risk of cardiovascular complication.
Literature
1.
Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S15–33.CrossRef
2.
Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A, Manolis A. The growing epidemic of diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):104–9.CrossRef
3.
Tinajero MG, Malik VS. An update on the epidemiology of type 2 diabetes: a global perspective. Endocrinol Metab Clin North Am. 2021;50(3):337–55.CrossRef
4.
Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21(6):45.CrossRef
5.
Association AD. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(Supplement 1):S125–50.CrossRef
6.
Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14(6):491–509.CrossRef
7.
Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020;18(2):110–6.CrossRef
8.
Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21(4):21.CrossRef
9.
Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017;1008:1–46.CrossRef
10.
Schmitz SU, Grote P, Herrmann BG. Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci. 2016;73(13):2491–509.CrossRef
11.
Guo J, Liu Z, Gong R. Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease. Clin Sci. 2019;133(12):1321–39.CrossRef
12.
Das S, Reddy MA, Natarajan R. Role of epigenetic mechanisms regulated by enhancers and long noncoding RNAs in cardiovascular disease. Curr Opin Cardiol. 2020;35(3):234–41.CrossRef
13.
Li X, Zhao Z, Gao C, Rao L, Hao P, Jian D, et al. The diagnostic value of whole blood lncRNA ENST00000550337.1 for pre-diabetes and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2017;125(6):377–83.CrossRef
14.
Wang H, Xia Y, Zhang Y. Diagnostic significance of serum lncRNA HOTAIR and its predictive value for the development of chronic complications in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2021;13(1):97.CrossRef
15.
Feng Y, Xu W, Zhang W, Wang W, Liu T, Zhou X. LncRNA DCRF regulates cardiomyocyte autophagy by targeting miR-551b-5p in diabetic cardiomyopathy. Theranostics. 2019;9(15):4558–66.CrossRef
16.
Zhang X, Gao Y, Zhang X, Zhang X, Xiang Y, Fu Q, et al. FGD5-AS1 is a hub lncRNA ceRNA in hearts with tetralogy of fallot which regulates congenital heart disease genes transcriptionally and epigenetically. Front Cell Dev Biol. 2021;9:630634.CrossRef
17.
Chen YX, Ding J, Zhou WE, Zhang X, Sun XT, Wang XY, et al. Identification and functional prediction of long non-coding RNAs in dilated cardiomyopathy by bioinformatics analysis. Front Genet. 2021;12:648111.CrossRef
18.
Yang X, Pratley RE, Tokraks S, Bogardus C, Permana PA. Microarray profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-sensitive and insulin-resistant Pima Indians. Diabetologia. 2002;45(11):1584–93.CrossRef
19.
Chinese Society of Cardiology of Chinese Medical Association CDP, of RCoCA. Chinese guideline on the primary prevention of cardiovascular diseases. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(12):1000–38.
20.
Joint Task Force for Guideline on the Assessment and Management of Cardiovascular Risk in China. Guideline on the assessment and management of cardiovascular risk in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2019;53(1):13–35.
21.
Zhong JY, Cui XJ, Zhan JK, Wang YJ, Li S, Lin X, et al. LncRNA-ES3 inhibition by Bhlhe40 is involved in high glucose-induced calcification/senescence of vascular smooth muscle cells. Ann NY Acad Sci. 2020;1474(1):61–72.CrossRef
22.
Yu ZW, Zhang J, Li X, Wang Y, Fu YH, Gao XY. A new research hot spot: the role of NLRP3 inflammasome activation, a key step in pyroptosis, in diabetes and diabetic complications. Life Sci. 2020;240:117138.CrossRef
23.
Chen Y, He Y, Zhou H. The potential role of lncRNAs in diabetes and diabetic microvascular complications. Endocr J. 2020;67(7):659–68.CrossRef
24.
Wu L, Zhu X, Song Z, Guo M, Liang J, Yan D. FGD5-AS1 facilitates glioblastoma progression by activation of Wnt/β-catenin signaling via regulating miR-129-5p/HNRNPK axis. Life Sci. 2020;256:117998.CrossRef
25.
Ge C, Dong J, Chu Y, Cao S, Zhang J, Wei J. LncRNA FGD5-AS1 promotes tumor growth by regulating MCL1 via sponging miR-153-3p in oral cancer. Aging. 2020;12(14):14355–64.CrossRef
26.
Fu J, Cai H, Wu Y, Fang S, Wang D. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis. Gene. 2020;755:144886.CrossRef
27.
Shen LS, Hu XF, Chen T, Shen GL, Cheng D. Integrated network analysis to explore the key mRNAs and lncRNAs in acute myocardial infarction. Math Biosci Eng. 2019;16(6):6426–37.CrossRef
28.
Valla M, Mjønes PG, Engstrøm MJ, Ytterhus B, Bordin DL, van Loon B, et al. Characterization of FGD5 expression in primary breast cancers and lymph node metastases. J Histochem Cytochem. 2018;66(11):787–99.CrossRef
29.
Cai X, Zhang P, Wang S, Hong L, Yu S, Li B, et al. lncRNA FGD5 antisense RNA 1 upregulates RORA to suppress hypoxic injury of human cardiomyocyte cells by inhibiting oxidative stress and apoptosis via miR-195. Mol Med Rep. 2020;22(6):4579–88.CrossRef
30.
Zhang XQ, Song LH, Feng SJ, Dai XM. LncRNA FGD5-AS1 acts as a competing endogenous RNA for miRNA-223 to lessen oxygen-glucose deprivation and simulated reperfusion (OGD/R)-induced neurons injury. Folia Neuropathol. 2019;57(4):357–65.CrossRef
31.
32.
Xia Y, Wang WC, Shen WH, Xu K, Hu YY, Han GH, et al. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC. Chem Biol Interact. 2021;349:109652.CrossRef
Metadata
Title
Diagnostic significance of serum FGD5-AS1 and its predictive value for the development of cardiovascular diseases in patients with type 2 diabetes
Authors
Yongdi Wang
Jian Wang
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2022
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-022-00789-x

Other articles of this Issue 1/2022

Diabetology & Metabolic Syndrome 1/2022 Go to the issue

Research

Alterations of the expression levels of glucose, inflammation, and iron metabolism related miRNAs and their target genes in the hypothalamus of STZ-induced rat diabetes model

Research

AK098656: a new biomarker of coronary stenosis severity in hypertensive and coronary heart disease patients

Research

The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial

Research

Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus

Review

The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials

Research

Obstructive sleep apnea risk and its associated factors among type 2 diabetes mellitus patients at wolkite university specialized hospital, Wolkite, Southern Ethiopia, 2021. A comparative cross-sectional study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits